Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that NFL analyst and philanthropist, Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, will serve as a brand ambassador for BOTOX® Cosmetic.
Harnessing Sanders’ trademark swagger, style and humor, Allergan also released two videos featuring Sanders sharing how he addressed his moderate to severe frown lines and crow’s feet with BOTOX® Cosmetic and showing men everywhere how the treatment may be right for them as well.
To view the multimedia release go to:
https://www.multivu.com/players/English/8174251-allergan-deion-sanders-botox/
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
CPhI Worldwide, organised by UBM Live, celebrates the closing of its most successful show to date with pre-audit figures estimating more than 34,000 attendees and 2,200 exhibitors. Held in Frankfurt, the show hosted senior-level decision makers and key players from 140+ countries representing every step of the pharmaceutical supply chain from drug discovery to finished dosage.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/63503-UBM-live-cphi-worldwide
CPhI Worldwide, organised by UBM EMEA, formally launches a new partnership with international charity Global Angels, to help promote its efforts and encourage support from the pharmaceutical industry.
The goal is to harness CPhI’s global reach to actively deliver support and funds from inside the pharma industry to Global Angels – a charity that partners with innovative projects to deliver tangible, life saving results in developing countries.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7522851-cphi-agreement-global-angels/
An injury ends Laura Nelson’s career as a surgeon. Now, as Vice President of a pharmaceutical company, Laura works to finalize the approval of a groundbreaking new drug. But her efforts are being thwarted by a malicious FDA employee who will stop at nothing to prevent the approval, and Laura is standing directly in his path. Find out more about the author here- http://patriciagussin.com/ and check out the book here http://oceanviewpub.com/after-the-fall/. After the Fall by Patricia Gussin. Thriller
ACG – the leading partner for pharmaceutical industry’s myriad requirements – is strengthening its product portfolio by launching several new machines at CPhI/P-MEC India, to be held during 2-4 December 2014, at Bombay Exhibition Centre, Mumbai.
P-MEC India, co-located with CPhI India, is one of the ‘must-attend’ events in the international pharmaceutical industry. With a booth that spreads over 1,000 sq. m., ACG will be displaying several new machines including the all-new ACG X.One Technology that reinvents the 12-bar safety features; Protab, a tablet press suited for small to medium batch sizes, and many more.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7391551-ACG-Launch-New-Machines-at-CPhI/
AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange.
With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in more than 170 countries, AbbVie launches with an estimated $18 billion in annual revenues and a strong commitment to creating shareholder value through long-term growth potential and the continuation of the company’s history of shareholder dividends.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company
Two Merck research scientists, Nancy A. Thornberry and Ann E. Weber, Ph.D., will receive the Discoverers Award, the highest honor from the Pharmaceutical Research and Manufacturers of America (PhRMA), during a ceremony tonight at the Liberty Science Center in Jersey City, N.J.
They will be recognized for their leadership in the discovery of JANUVIA®, a once-daily pill that helps patients with type 2 diabetes control glucose in conjunction with diet and exercise. Though women have been part of teams honored with the Discoverers Award in the past, this is the first time in the award’s 24-year history that women alone have won.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/49723/
